Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial

American Journal of Drug and Alcohol Abuse

Volumn 37, Issue 5, 2011, Pages 313-323

  Back, Sudie E ^a   Payne, Rebecca L ^a   Wahlquist, Amy Herrin ^b   Carter, Rickey E ^c   Stroud, Zachary ^a   Haynes, Louise ^a   Hillhouse, Maureen ^d   Brady, Kathleen T ^a   Ling, Walter ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical Trials Network; Gender; Opioids; Prescription drugs; Sex

Indexed keywords

AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; CANNABIS; COCAINE; DIAMORPHINE; METHADONE; METHAMPHETAMINE; MORPHINE; NICOTINE; OXYCODONE; PHENCYCLIDINE; PSYCHEDELIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADDICTION SEVERITY INDEX LITE; ADJECTIVE RATING SCALE FOR WITHDRAWAL; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL OPIATE WITHDRAWAL SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; EMPLOYMENT STATUS; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HELP SEEKING BEHAVIOR; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MUSCULOSKELETAL DISEASE; NATIONAL HEALTH ORGANIZATION; OPIATE ADDICTION; RATING SCALE; RESPIRATORY TRACT DISEASE; SEIZURE; SEX DIFFERENCE; STRUCTURED INTERVIEW; UROGENITAL TRACT DISEASE; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 80052230258     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2011.596982     Document Type: Article

References (51)

1. Hopfer CJ, Mikulich SK, Crowley TJ. Heroin use among adolescents in treatment for substance use disorders. J Am Acad Child Adolesc Psychiatry 2000; 39(10): 1316-1323.
2. Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: A review of the descriptive and treatment literature. J Subst Abuse Treat 2002; 23(3):231-237. (Pubitemid 35254166)
3. Substance Abuse and Mental Health Services Administration. Results from the 2002 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, 2003.
4. Back SE, Payne RA, Simpson AN, Brady KT. Gender and prescription opioids: Findings from the National Survey on Drug Use and Health. Addict Behav 2010; 35: 1001-1007.
5. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, 2007.
6. Substance Abuse and Mental Health Services Administration. Treatment Episode Data Set (TEDS) Highlights - 2006 National Admissions to Substance Abuse Treatment Services. Rockville, MD: Office of Applied Studies, 2007.
7. Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective. Clin J Pain 2006; 22(8): 667-676. (Pubitemid 44434948)
8. Tamayo-Sarver JH, Dawson NV, Cydulka RK, Wigton RS, Baker DW. Variability in emergency physician decision making about prescribing opioid analgesics. Ann Emerg Med 2004; 43(4):483-493. (Pubitemid 38436538)
9. Brady KT, Back SE, Greenfield S. Women and Addiction: A Comprehensive Handbook. New York, NY: Guilford Press, 2009.
10. Darke S, Ross J, Teesson M, Lynskey M. Health service utilization and benzodiazepine use among heroin users: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 2003; 98(8):1129-1135. (Pubitemid 36936499)
11. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid- , cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend 2004; 74(3):265-272. (Pubitemid 38759781)
12. Hser YI, Anglin DA, Booth MW. Sex differences in addict careers. Am J Drug Alcohol Abuse 1987; 13(3): 231-251.
13. Kosten TR, Rounsaville BJ, Kleber HD. Ethnic and gender differences among opiate addicts. Int J Addict 1985; 20(8):1143-1162. (Pubitemid 16213145)
14. Randall CR, Roberts JS, Del Boca FK, Carroll KM, Connors GJ, Mattson ME. Telescoping of landmark events associated with drinking: A gender comparison. J Stud Alcohol 1999; 60(2):252-260. (Pubitemid 29091608)
15. Simoni-Wastila L, Ritter G, Strickler G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst Use Misuse 2004; 39(1): 1-23. (Pubitemid 38251904)
16. Rosenblum A, Parrino M, Schnoll SH, Fong C, Maxwell C, Cleland CM, Magura S, Haddox JD. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007; 90(1):64-71. (Pubitemid 46935374)
17. Green TC, Serrano JMG, Licari A, Budman SH, Butler SF. Women who abuse prescription opioids: Findings from the Addiction Severity Index - Multimedia Version Connect® prescription opioid database. Drug Alcohol Depend 2009; 103(1-2):65-73.
18. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: Results from a national US survey. Addiction 2008; 103(2):258-268.
19. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of Oxy- Contin and other opioid analgesics in the United States: 2002-2004. J Pain 2005; 6(10):662-672. (Pubitemid 41395058)
20. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007; 164(11):1750-1756. (Pubitemid 350205353)
21. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse, and dependence on prescription opioids among US adults: Psychiatric, medical, and substance use correlates. Drug Alcohol Depend 2008; 94(1-3): 38-47.
22. Back SE, Payne RA, Waldrop AE, Smith A, Reeves S, Brady KT. Prescription opioid aberrant behaviors: A pilot study of sex differences. Clin J Pain 2009; 25(6): 477-484.
23. McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav 2007; 32(3): 562-575. (Pubitemid 46038570)
24. McCabe SE, Teter CJ, Boyd CJ, Knight JR, Wechsler H. Nonmedical use of prescription opioids among U.S. college students: Prevalence and correlates from a national survey. Addict Behav 2005; 30(4):789-805. (Pubitemid 40516844)
25. McCabe SE, Teter CJ, Boyd CJ. Illicit use of prescription pain medication among college students. Drug Alcohol Depend 2005; 77(1):37-47. (Pubitemid 39656098)
26. Substance Abuse andMental Health Services Administration. The NSDUH Report: Patterns and Trends in Nonmedical Prescription Pain Reliever Use: 2002 to 2005. Rockville, MD: Office of Applied Studies, 2007.
27. Boyd CJ, McCabe SE, Teter CJ. Medical and nonmedical use of prescription pain medication use by youth in a Detroitarea public school district. Drug Alcohol Depend 2006; 81(1): 37-45.
28. Wu LT, Pilowsky D, Patkar AA. Non-prescribed use of pain relievers among adolescents in the United States. Drug Alcohol Depend 2008; 94(1-3):1-11. (Pubitemid 351249105)
29. Substance Abuse Mental Health Services Administration. The NSDUH Report: Demographic and Geographic Variations in Injection Drug Use. Rockville,MD: Office of Applied Studies, 2007.
30. Wu LT, Howard MO. Is inhalant use a risk factor for heroin and injection drug use among adolescents in the United States? Addict Behav 2007; 32(2):265-281. (Pubitemid 44918210)
31. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R. The characteristics of heroin users entering treatment: Findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev 2005; 24(5): 411-418. (Pubitemid 43024040)
32. Darke S, Ross J. Suicide among heroin users: Rates, risk factors and methods. Addiction 2002; 97(11):1383-1394. (Pubitemid 35316211)
33. Darke S, Hall W. Levels and correlates of polydrug use among heroin users and regular amphetamine users. Drug Alcohol Depend 1995; 39(3):231-235.
34. Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse 1999; 34(8):1137-1165. (Pubitemid 29264248)
35. Ling W, Hillhouse M, Domier C, Doraimani G, Hunter J, Thomas C, Jenkins J, Hasson A, Annon J, Saxon A, Selzer J, Boverman J, Bilangi R. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009; 104(2): 256-265.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Press, 2000.
37. Cacciola JS, Alterman AI, McLellan AT, Lin YT, Lynch KG. Initial evidence for the reliability and validity of a Lite version of the Addiction Severity Index. Drug Alcohol Depend 2007; 87(2-3):297-302. (Pubitemid 46217911)
38. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: Comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43(1): 72-78. (Pubitemid 18052024)
39. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003; 35(2): 253-259. (Pubitemid 36927370)
40. Childress AR, McLellan AT, OBrien CP. Abstinent opiate abusers exhibit conditioned craving, conditioned withdrawal and reductions in both through extinction. Br J Addict 1986; 81(5):655-660. (Pubitemid 17203143)
41. Kaplan RF, Cooney NL, Baker LH, Gillespie RA, Meyer RE, Pomerleau OF. Reactivity to alcohol-related cues: Physiological and subjective responses in alcoholics and nonproblem drinkers. J Stud Alcohol 1985; 46(4): 267-272. (Pubitemid 15004347)
42. DiPaula BA, Schwartz R, Montoya ID, Barrett D, Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. J Subst Abuse Treat 2002; 23(3): 163-169. (Pubitemid 35254158)
43. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S. Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): Prevalence, correlates and treatment seeking. Drug Alcohol Depend 2005; 78(3):309-315. (Pubitemid 40694053)
44. Oreskovich MR, Saxon AJ, Ellis MLK, Malte CA, Reoux JP, Knox PC. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 2005; 77(1):71-79. (Pubitemid 39656101)
45. Ponizovsky AM, Grinshpoon A, Margolis A, Cohen R, Rosca P. Well-being, psychosocial factors, and sideeffects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine. Addict Behav 2006; 31(11):2002-2013. (Pubitemid 44548184)
46. White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: An open-label comparison of lofexidine and buprenorphine. Drug Alcohol Depend 2001; 65(1):77-83. (Pubitemid 33063663)
47. Potter JS, Hennessy G, Borrow JA, Greenfield SF, Weiss RD. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence. Drug Alcohol Depend 2004; 76(2):213-215. (Pubitemid 39370817)
48. Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoys I, Fischman MW, Collins J, McSherry F, Boardman K, Davies DK, OBrien CP, Ling WL, Kleber H, Herman BHA. Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 2008; 97(1-2):158-168.
49. Compton WM, Cottler LB, Abdallah AB, Phelps DL, Spitznagel EL, Hortone JC. Substance dependence and other psychiatric disorders among drug dependent subjects: Race and gender correlates. Am J Addict 2000; 9(2):113-125. (Pubitemid 30419109)
50. Brady KT, Randall CL. Gender differences in substance use disorders. Psychiatr Clin North Am 1999; 22(2): 41-52.
51. Fox HC, Sinha R. Sex differences in drug-related stress-system changes: Implications for treatment in substance-abusing women. Harv Rev Psychiatry 2009; 17(2): 103-119.